A federal jury in California has ruled in favor of drugmaker Merck & Co. in a high-stakes lawsuit against rival Gilead Sciences Inc. over patents for lucrative new drugs that rapidly cure hepatitis C. Merck accused Gilead of infringing on patents it filed over a decade ago, claiming Gilead’s sofosbuvir infringes on those patents. Merck is seeking billions in damages and royalties on sales of Gilead’s two hepatitis drugs.